Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02755597
Title A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors AbbVie

multiple myeloma


Bortezomib + Dexamethasone

Bortezomib + Dexamethasone + Venetoclax

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN

No variant requirements are available.